Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue
Total revenues	$ 32,868	$ 59,221	$ 103,213	$ 145,863
Royalties
Disaggregation of Revenue
Total revenues	23,863	19,255	61,447	50,507
Kyprolis
Disaggregation of Revenue
Total revenues	10,537	9,123	24,862	20,872
Evomela
Disaggregation of Revenue
Total revenues	2,497	3,123	7,404	8,218
Teriparatide injection
Disaggregation of Revenue
Total revenues	2,800	4,071	9,913	12,484
Rylaze
Disaggregation of Revenue
Total revenues	3,678	2,099	9,315	6,065
Other
Disaggregation of Revenue
Total revenues	4,351	839	9,953	2,868
Captisol
Disaggregation of Revenue
Total revenues	8,608	35,949	24,450	77,616
Captisol - Core
Disaggregation of Revenue
Total revenues	8,608	3,582	24,450	13,133
Captisol - COVID
Disaggregation of Revenue
Total revenues	0	32,367	0	64,483
Contract revenue
Disaggregation of Revenue
Total revenues	397	4,017	17,316	17,740
Service revenue
Disaggregation of Revenue
Total revenues	263	90	534	1,047
Milestone
Disaggregation of Revenue
Total revenues	0	2,658	15,300	8,651
Other
Disaggregation of Revenue
Total revenues	$ 134	$ 1,269	$ 1,482	$ 8,042